Kyongbo Pharmaceutical Co., Ltd
Research Kyongbo Pharmaceutical Co., Ltd (214390.KS) on Bullrun: market cap KRW 125.51B, dividend yield 1.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker214390.KS
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 125.51B
- Dividend yield1.0%
- Financial periodQ2 2026
- RevenueKRW 75.22B
- Net incomeKRW 2.97B
- Free cash flow-KRW 17.49B
- Gross margin38.1%
Valuation Snapshot
latest market cap is KRW 125.51B; dividend yield is 1.0%.
Peer valuation comparison
Latest dividend yield is 1% versus a Healthcare sector median of 2.4% (58.3% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 125.51B | n/a | 1.0% | 50 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 50 KRW, yield 1.0%.
About Kyongbo Pharmaceutical Co., Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE.
ETFs that hold Kyongbo Pharmaceutical Co., Ltd
US-listed ETFs
Kyongbo Pharmaceutical Co., Ltd is held by one US-listed ETF, going by the latest portfolio it filed with the SEC:
| ETF | Weight | Fee |
|---|---|---|
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kyongbo Pharmaceutical Co., Ltd's market cap?
Kyongbo Pharmaceutical Co., Ltd's market capitalization is KRW 125.51B.
Does Kyongbo Pharmaceutical Co., Ltd pay a dividend?
Kyongbo Pharmaceutical Co., Ltd has a dividend yield of 1.0%.
What does Kyongbo Pharmaceutical Co., Ltd do?
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE.